Join
Live feed
·
PRReleasevia Quantisnow
Immunic Inc. logo

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders

ByQuantisnow·Wall Street's wire, on your screen.
IMUX· Immunic Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMUX (Immunic Inc.) and more on Quantisnow.